Androgen Profile Through Life in Women With Polycystic Ovary Syndrome: A Nordic Multicenter Collaboration Study

Pinola, Pekka; Piltonen, Terhi; Puurunen, Johanna; Vanky, Eszter; Sundström‐Poromaa, Inger; Stener-Victorin, Elisabet; Ruokonen, Aimo; Puukka, Katri; Tapanainen, Juha S.; Morin‐Papunen, Laure

doi:10.1210/jc.2015-2123

Cited by 76 publications

(64 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Finally, assuming that the AMH cutpoints for PCOS are similar in women with and without type 1 diabetes, perhaps women with type 1 diabetes less commonly have PCOS than women without diabetes. Since ovarian hormones decline with age among women with PCOS (36), these differences are less marked between women with and without diabetes at older ages.…”

Section: Discussionmentioning

confidence: 99%

Antimüllerian hormone among women with and without type 1 diabetes: the Epidemiology of Diabetes Interventions and Complications Study and the Michigan Bone Health and Metabolism Study

Kim

Karvonen‐Gutierrez

Kong

et al. 2016

Fertility and Sterility

View full text Add to dashboard Cite

Structured Abstract Objective To compare concentrations of anti-Müllerian hormone (AMH) in women with and without type 1 diabetes. Design Cross-sectional analysis of longitudinal studies adjusting for repeated measures Setting Michigan Bone Health and Metabolism Study (MBHMS), a community-based population and the Epidemiology of Interventions and Complications Study (EDIC), an observational cohort of women with type 1 diabetes. Participants Women who were aged 30–45 years and had not undergone oophorectomy, hysterectomy, or natural menopause at the time of AMH measurement were included (n=376 in MBHMS and n=321 in EDIC). Linear mixed regression was used to evaluate whether AMH concentrations differed by diabetes status adjusting for repeated measurements of AMH within individual women, body mass index, smoking status, and oral contraceptive use. Interventions None Main Outcome Measure AMH concentrations Results Prior to 35 years of age, logAMH concentrations were significantly lower among women with type 1 diabetes compared to women without diabetes (β-coefficient −1.27, 95% confidence interval [−2.18, −0.36] in fully-adjusted models). Conclusions Prior to 35 years of age, women with type 1 diabetes have lower AMH levels than women without diabetes. Further investigation is needed to determine the etiologies of this difference and how it may contribute to reproductive disorders among women with type 1 diabetes.

show abstract

Section: Discussionmentioning

confidence: 99%

Antimüllerian hormone among women with and without type 1 diabetes: the Epidemiology of Diabetes Interventions and Complications Study and the Michigan Bone Health and Metabolism Study

Kim

Karvonen‐Gutierrez

Kong

et al. 2016

Fertility and Sterility

View full text Add to dashboard Cite

show abstract

“…The enhanced insulin resistance in obesity was reflected in the decrease in the SHBG levels particularly in the obese PCOS subjects resulting in an increased FAI. There is little data on the role ADTG in PCOS and androgen metabolism, however this study showing the increased ADTG: DHEAS ratio in obese PCOS using state of the art measurement free from assay interference addresses the discrepancy noted in one study that it was not correlated with PCOS [8, 18], and with another suggesting that ADTG levels are increased [13]. …”

Section: Discussionmentioning

confidence: 74%

“…It has been shown that conversion of DHEAS to ADTG occurs mainly through hepatic 5α-reductase activity, and to a lesser extent peripheral 5α-reductase activity [9–11]. It is reported that hepatic 5α-reductase activity is increased in insulin resistant states [18] and it can be seen from the results that the obese PCOS patients were significantly more insulin resistant than the non-obese PCOS patients and the normal controls (the HOMA-IR did not differ between the non-obese PCOS and normal subjects) suggesting that the increased insulin resistance in obesity may be driving the hepatic 5α-reductase activity converting DHEAS to ADTG. The enhanced insulin resistance in obesity was reflected in the decrease in the SHBG levels particularly in the obese PCOS subjects resulting in an increased FAI.…”

Section: Discussionmentioning

confidence: 99%

Androsterone glucuronide to dehydroepiandrosterone sulphate ratio is discriminatory for obese Caucasian women with polycystic ovary syndrome

et al. 2017

View full text Add to dashboard Cite

BackgroundAndrosterone glucuronide (ADTG) concentrations have been suggested as a marker of the effects of androgens at the target tissue level. As the mechanism for hyperandrogenemia in obese and nonobese polycystic ovary syndrome (PCOS) may differ, this study compared the different androgen parameters in non-obese compared to obese women with PCOS, and in normal subjects.MethodsEleven non-obese and 14 obese women with PCOS were recruited and compared to 11 control women without PCOS. Total testosterone, dehydroepiandrosterone sulphate (DHEAS), ADTG, and androstenedione were analysed using gold standard tandem mass spectrometry, and the free androgen index (FAI) was calculated.ResultsTotal testosterone, ADTG and androstendione levels did not differ between non-obese (body mass index (BMI) ≤25 kg/m2) and obese PCOS (BMI >25 kg/m2) but all were significantly higher than for controls (p < 0.01). The ADTG to DHEAS ratio was significantly elevated 39 ± 6 (p < 0.01) in obese PCOS in comparison to non-obese PCOS and controls (28 ± 5 and 29 ± 4, respectively). The free androgen index (FAI) and insulin resistance (HOMA-IR) were significantly higher in obese PCOS compared to non-obese PCOS and controls (p < 0.01). DHEAS was significantly higher in the non-obese versus obese PCOS (p < 0.01). All androgen parameters were significantly lower and sex hormone binding globulin (SHBG) significantly higher in normal subjects compared to those with obese and non-obese PCOS.ConclusionsThe ADTG:DHEAS ratio was significantly elevated in obese PCOS compared to non-obese PCOS and controls suggesting that this may be a novel biomarker discriminatory for obese PCOS subjects, perhaps being driven by higher hepatic 5α reductase activity increasing ADTG formation in these women.

show abstract

“…According to research, these parameter elevations are commonly utilised as hyperandrogenaemia biomarkers in PCOS (Pinola et al, 2015). This suggests that PCOS is regarded as a disorder caused by increased androgen biosynthesis, usage or metabolism as reiterated by Azziz et al (2006).…”

Section: Discussionmentioning

confidence: 99%

Therapeutic Potential of Metformin and Vitex Agnus-Castus In Alleviating Cardiac Damage Induced By Hyperandrogenism In Polycystic Ovary Female Rats

2017

Aust. J. Basic & Appl. Sci.

View full text Add to dashboard Cite

To Cite This Article: Widad M. Al-Bishri Therapeutic potential of metformin and Vitex agnus-castus in alleviating cardiac damage induced by hyperandrogenism in polycystic ovary female rats Aust. J. Basic & Appl. Sci., 11(14): [129][130][131][132][133][134][135][136][137][138] 2017 This research was aimed at exploring the profound therapeutic impacts of metformin (Met) and Vitex agnus-castus fruit (Vit) on cardiovascular risk factors, which includes dyslipidaemia, hyperhomocysteinemia and hyperleptinemia as well as hypoadiponectinemia. Others are hyperprolactinemia as well as DNA oxidative damage. These factors are generated by hyperandrogenism in Poly-Cystic Ovarian Syndrome (PCOS) female rats. The task involved inducing PCOS in rats using an oral ingestion of letrozole of 1mg/kg once a day for twenty-one days. Rats, which were induced with PCOS, were treated orally with either Met of 70 mg/kg single dose or Vit fruit amounting to 500mg/kg daily for 21 days after PCO induction. The findings indicate that giving rats induced with PCOS Met or Vit significantly ameliorated the increases in hyperandrogenism markers, including androstendione, Dehydroepiandrosterone Sulfate (DHEAS) and total testosterone as well as free testosterone in comparison with PCOS untreated ones. The two agents did modulation of the reduction in the content of serum of apolipoprotein (apo) A. Additionally; they elevated total lipid as well as apo B of rats with PCOS. Furthermore, the findings showed Met or Vit significantly ameliorating the serum hyperhomocysteinemia, hyperleptinemia, hypoadiponectinemia and hyperprolactinemia. There was also the increase in 8-hydroxydeoxyguanosine (8-OHdG) in PCOS rats, when compared to PCOS untreated rats. It became evident that Met and Vit could modulate the increases in the serum cardiac damage markers such as troponine T and alkaline phosphatase (ALP) as well as lactate dehydrogenase (LDH) in the PCOS induced rats. Finally, it became clear through the findings that treating PCOS rats using Vit could yield more efficient results in modulation of most the studied markers compared to Met. Conclusion: Met or Vit can be used to reduce cardiovascular risk. This is as a result of Met and Vit effective showing the ability that they can modulate cardiovascular risk elements in the PCOS induced rats utilised. However; Vit proved to be more potent than Met as far as this therapy went and this explained why Vit fruit is used in managing PCOS related cardiovascular events.

show abstract

Androgen Profile Through Life in Women With Polycystic Ovary Syndrome: A Nordic Multicenter Collaboration Study

Cited by 76 publications

References 42 publications

Antimüllerian hormone among women with and without type 1 diabetes: the Epidemiology of Diabetes Interventions and Complications Study and the Michigan Bone Health and Metabolism Study

Antimüllerian hormone among women with and without type 1 diabetes: the Epidemiology of Diabetes Interventions and Complications Study and the Michigan Bone Health and Metabolism Study

Androsterone glucuronide to dehydroepiandrosterone sulphate ratio is discriminatory for obese Caucasian women with polycystic ovary syndrome

Therapeutic Potential of Metformin and Vitex Agnus-Castus In Alleviating Cardiac Damage Induced By Hyperandrogenism In Polycystic Ovary Female Rats

Contact Info

Product

Resources

About